Cipla Share Price in Focus Following Formation of Joint Venture in Biologics

Cipla to Incorporate Joint Venture Company with Kemwell Biopharma

Cipla, a leading pharmaceutical company, has announced plans to form a joint venture company in India with Kemwell Biopharma, a biologics Contract Development and Manufacturing Organization (CDMO).

Key Highlights:

• The proposed joint venture will be a 60:40 partnership between Cipla and Kemwell, with initial investments of up to ₹10 crore in their respective shareholding ratio.
• Cipla will subscribe to 6,000 shares of ₹10 each at par, amounting to ₹60,000.
• The joint venture will focus on developing, manufacturing, and commercializing biologic products, as well as engaging in licensing or outsourcing activities.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

About Kemwell Biopharma:

• Kemwell Biopharma is an Asia-based biologics CDMO offering end-to-end services for global biopharma clients.
• Its Bengaluru-based cGMP facility is certified by the USFDA and features a 5,000-litre bioreactor capacity, sterile fill–finish capabilities, and advanced development laboratories for protein therapeutics.

Market Performance:

• Cipla's share closed at Rs 1,351.85 in the previous trading session, up Rs 4.20, or 0.31 percent.
• The share has touched a 52-week high of Rs 1,672.20 and a 52-week low of Rs 1,283.00 on 23 October, 2025 and 27 January, 2026, respectively.
• The stock is currently trading 19.16 percent below its 52-week high and 5.37 percent above its 52-week low.
• The market capitalization of Cipla stands at Rs 109,199.83 crore.

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year